Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma

NCT05226494 is registered in ClinicalTrials.gov with NanoPharmaceuticals LLC as lead sponsor.

NCT NCT05226494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05226494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma
Lead sponsor
NanoPharmaceuticals LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 23, 2022
Completion date
June 30, 2028
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, malignant